Navigation Links
PeaceHealth Laboratories' New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse
Date:5/30/2012

SPRINGFIELD, Ore., May 30, 2012 /PRNewswire/ -- PeaceHealth Laboratories today announced the national availability and receipt of a federal patent for PtProtect™ (Patient Protect), a pain medication monitoring program offering the industry's highest levels of accuracy to detect prescription pain medication and identify potential negative drug interactions before they occur. PtProtect directly addresses the safety and financial concerns of prescription pain medication abuse by using the most sensitive and definitive assays to detect medication and illicit drugs.

In the most recent review period January – April, 2012, PeaceHealth Laboratories found that 35 percent of PtProtect test results returned discrepant results outside a patient's known prescriptions. Because PtProtect identifies patients who are taking or potentially diverting prescribed pain medications, taking pain medications that are not prescribed to them, or using drugs of abuse it has the potential to significantly reduce accidental deaths. (1)

"PtProtect saves lives, saves practices and saves communities money," said Ran Whitehead, Chief Executive Officer of PeaceHealth Laboratories. "Now physicians may know, with confidence, what pain medications their patient is taking and prescribe accordingly to the highest levels of safety. This patent validates our rigorous science and practical application of this life-saving technology. It also enables providers to protect their practices from uncertain liabilities including malpractice and patient mortality."

In recognition of PtProtect's technology and capabilities, the U.S. Patent and Trademark Office issued U.S. Patent No. 8,067,243 granting exclusive rights to PtProtect™.  

About PtProtect

PtProtect is a patented testing program that detects up to 38 prescribed medications and illicit drugs. Medications are revealed at the industry's lowest thresholds for the most sensitive, comprehensive detection of opiates and opioids, thus reducing the possibility of adverse drug interactions. Simple and timely reporting allows doctors to quickly determine if test results are consistent or inconsistent with patient prescriptions.

PtProtect is available through PeaceHealth Laboratories and may be administered by physicians nationwide. For information about PtProtect, visit www.ptprotect.com or call 800-826-3616.

About PeaceHealth Laboratories

PeaceHealth Laboratories is a division of PeaceHealth, a not-for-profit health care system with a mission of promoting personal and community health since 1890. PeaceHealth Laboratories provides comprehensive laboratory services throughout the Pacific Northwest (Oregon, Washington and Alaska), and specialty testing for clinicians and employers across the U.S. With 9 laboratories and 27 patient service centers in three states, PeaceHealth Laboratories is one of the largest laboratory systems in the Pacific Northwest. Learn more at www.peacehealthlabs.org

(1) Source: CNNMoney February 24, 2012


'/>"/>
SOURCE PeaceHealth Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PeaceHealth Standardizes Hematology Operations With Sysmex
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
4. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
5. Romark Laboratories Raises $18 Million in Institutional Financing
6. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
7. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
8. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
9. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
10. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
11. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):